What I want to see goes beyond the current pain points of mRNA therapeutics; it needs to be more direct. Do you feel that mRNA applications are currently concentrated on vaccine development? This business logic is tied to US health insurance and genomic sequencing, which is one key point.
Another point: how can we expand mRNA beyond vaccines, genetic diseases, and rare diseases? What's missing right now? Who has the capability?
Are there payment pathways outside the current commercial insurance system?
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.